JPMorgan Chase & Co. began coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research note published on Monday morning, Marketbeat.com reports. The firm issued an overweight rating and a $35.00 target price on the stock. A number of other research analysts have also recently issued reports on the company. Capital One […]
Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) in a report issued on Monday, MarketBeat reports. The firm set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 40.51% from the […]
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s share price fell 3.2% during mid-day trading on Friday . The stock traded as low as $21.85 and last traded at $22.12. 116,776 shares were traded during mid-day trading, a decline of 88% from the average session volume of 962,950 shares. The stock had previously closed at […]
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 4,750,000 shares, a decrease of 32.2% from the November 30th total of 7,010,000 shares. Based on an average trading volume of 1,310,000 shares, […]
Capital One Financial began coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report released on Monday morning, Benzinga reports. The firm issued an overweight rating and a $44.00 target price on the stock. Capital One Financial also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.76) EPS, FY2023 earnings […]